- Home
- CCK vs QGEN Comparison
CCK vs QGEN Comparison
Compare CCK & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCK | QGEN |
|---|---|---|
| Founded | 1906 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 10.2B |
| IPO Year | 2003 | 1998 |
Fundamental Metrics
Financial Performance| Metric | CCK | QGEN |
|---|---|---|
| Price | $95.76 | $36.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 8 |
| Target Price | ★ $121.19 | $45.76 |
| AVG Volume (30 Days) | 1.0M | ★ 2.0M |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | 1.41% | ★ 7.17% |
| EPS Growth | ★ 79.72 | N/A |
| EPS | ★ 1.56 | N/A |
| Revenue | ★ $11,665,000,000.00 | N/A |
| Revenue This Year | $5.17 | $8.18 |
| Revenue Next Year | $2.38 | $5.71 |
| P/E Ratio | $62.51 | ★ $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $89.21 | $32.53 |
| 52 Week High | $116.62 | $57.82 |
Technical Indicators
Market Signals| Indicator | CCK | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 38.84 | 56.56 |
| Support Level | $93.91 | $32.85 |
| Resistance Level | $102.17 | $48.53 |
| Average True Range (ATR) | 2.19 | 0.80 |
| MACD | 0.02 | 0.64 |
| Stochastic Oscillator | 20.42 | 94.23 |
Price Performance
Historical ComparisonAbout CCK Crown Holdings Inc.
Crown Holdings Inc is a producer of metal packaging. The company manufactures beverage cans, metal food cans, and closures, as well as aerosol cans. With the purchase of Signode, the company also has a presence in a wide variety of protective transport packaging. Although it's headquartered in the United States, the vast majority of Crown's sales come from its operations in Europe, South America, and Southeast Asia.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).